Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials.

Autor: Andresen NK; Department of Clinical Cancer Research, Oslo University Hospital, Norway.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Norway.; Institute of Clinical Medicine, University of Oslo, Norway., Røssevold AH; Department of Clinical Cancer Research, Oslo University Hospital, Norway.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Norway.; Institute of Clinical Medicine, University of Oslo, Norway., Borgen E; Department of Pathology, Oslo University Hospital, Norway., Schirmer CB; Department of Pathology, Oslo University Hospital, Norway., Gilje B; Department of Hematology and Oncology, Stavanger University Hospital, Norway., Garred Ø; Department of Pathology, Oslo University Hospital, Norway., Lømo J; Department of Pathology, Oslo University Hospital, Norway., Stensland M; Department of Hematology and Oncology, Stavanger University Hospital, Norway., Nordgård O; Department of Hematology and Oncology, Stavanger University Hospital, Norway.; Department of Chemistry, Bioscience and Environmental Technology, University of Stavanger, Norway., Falk RS; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Norway., Mathiesen RR; Department of Oncology, Oslo University Hospital, Norway., Russnes HG; Institute of Clinical Medicine, University of Oslo, Norway.; Department of Pathology, Oslo University Hospital, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Norway., Kyte JA; Department of Clinical Cancer Research, Oslo University Hospital, Norway.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Norway.; Faculty of Health Sciences, Oslo Metropolitan University, Norway., Naume B; Institute of Clinical Medicine, University of Oslo, Norway.; Department of Oncology, Oslo University Hospital, Norway.

Publikováno v: Molecular oncology [Mol Oncol] 2024 Jul 08. Date of Electronic Publication: 2024 Jul 08.

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.

Autor: Andresen NK; Department of Clinical Cancer Research and Department of Cancer Immunology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Røssevold AH; Department of Clinical Cancer Research and Department of Cancer Immunology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Quaghebeur C; Department of Oncology, CHU UCL Namur - Site Sainte-Elisabeth, Namur, Belgium., Gilje B; Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway., Boge B; Center for Cancer Treatment, Sørlandet Hospital Kristiansand, Kristiansand, Norway., Gombos A; Department of Medical Oncology, Institut Jules Bordet, Bruxelles, Belgium., Falk RS; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway., Mathiesen RR; Department of Oncology, Oslo University Hospital, Oslo, Norway., Julsrud L; Department of Radiology and Nuclear medicine, Oslo University Hospital, Oslo, Norway., Garred Ø; Department of Pathology, Oslo University Hospital, Oslo, Norway., Russnes HG; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Pathology and Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway., Lereim RR; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Chauhan SK; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Lingjærde OC; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway., Dunn C; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Naume B; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway., Kyte JA; Department of Clinical Cancer Research and Department of Cancer Immunology, Oslo University Hospital, Oslo, Norway jonky@ous-hf.no.; Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jan 19; Vol. 12 (1). Date of Electronic Publication: 2024 Jan 19.

How I treat endocrine-dependent metastatic breast cancer.

Autor: Gombos A; Department of Medical Oncology Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Goncalves A; Institut Paoli Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS U7258, Aix Marseille University, Marseille, France., Curigliano G; European Institute of Oncology, University of Milano, Milano, Italy., Bartsch R; Department of Medicine I, Medical University of Vienna, Vienna, Austria., Kyte JA; Department of Oncology, Oslo University Hospital, Oslo, Norway., Ignatiadis M; Department of Medical Oncology Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Awada A; Department of Medical Oncology Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: ahmad.awada@bordet.be.

Publikováno v: ESMO open [ESMO Open] 2023 Apr; Vol. 8 (2), pp. 100882. Date of Electronic Publication: 2023 Feb 17.